Actimmune Market Report 2026

Actimmune Market Overview

• The Actimmune market growth in the historic period has been driven by lack of alternative therapies for cgd, proven efficacy of interferon gamma therapy • Market expansion is supported by rising diagnosis of rare immune disorders, increased access to specialty immunology centers • Growth Driver: Rising Incidence Of Infectious Diseases Driving Actimmune Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Actimmune Market?

Actimmune refers to a brand name for the drug interferon gamma-1b, a synthetic version of a naturally occurring protein that helps regulate the immune system. It is used to treat chronic granulomatous disease (CGD) and severe, malignant osteopetrosis by boosting the immune system to fight infections and improve bone strength. The main indications for actimmune are chronic granulomatous disease (CGD), severe malignant osteopetrosis, and others. Chronic Granulomatous Disease (CGD) is a rare, inherited immunodeficiency disorder characterized by the inability of certain white blood cells to kill specific bacteria and fungi, leading to recurrent infections and granuloma formation. Patient groups in this are pediatric, adult, and others. It is distributed by various channels such as hospital pharmacies, specialty pharmacies, and online pharmacies, facilitating broad accessibility to the medication.

What Is The Actimmune Market Growth Forecast?

The growth in the forecast period can be attributed to rising diagnosis of rare immune disorders, increased access to specialty immunology centers, long term therapy adherence focus, supportive reimbursement frameworks, continued orphan drug investment. Major trends in the forecast period include growing use in rare immunodeficiency disorders, increased focus on immune modulation therapies, expansion of long term immune support treatments, improved management of chronic granulomatous disease, rising adoption in specialized immunology care.

What Are The Drivers Of The Actimmune Market?

The rising incidence of infectious diseases is expected to propel the growth of the actimmune market going forward. Infectious diseases are illnesses caused by harmful microorganisms like bacteria, viruses, fungi, or parasites that invade the body, often spreading through direct contact, contaminated surfaces, or vectors, and can range in severity based on the pathogen and immune response. The rising incidence of infectious diseases is due to factors like population growth, poor sanitation, climate change, and the spread of new pathogens. Actimmune contributes to combating infectious diseases by enhancing the immune system's ability to identify and eliminate pathogens, including specific bacteria and viruses. It supports immune responses through the activation of macrophages and other immune cells, playing a crucial role in managing infections and reducing the severity of complications associated with immune deficiencies or chronic infections. For instance, in February 2024, according to the UK Health Security Agency, a UK-based government department, tuberculosis (TB) cases in England rose by 10.7% in 2023, increasing from 4,380 in 2022 to 4,850. Therefore, the rising incidence of infectious diseases is driving the actimmune industry. The rising prevalence of chronic diseases is expected to propel the growth of the actimmune markets going forward. Chronic diseases refer to long-lasting conditions that persist for a year or more and require ongoing medical attention or limit daily activities. The rising prevalence of chronic diseases is attributed to factors like aging, unhealthy lifestyles, environmental influences, genetics, and better diagnosis. Actimmune helps chronic diseases by modulating the immune response and reducing inflammation, making it effective in managing conditions such as chronic granulomatous disease and severe malignant osteopetrosis, where it enhances immune function and mitigates disease progression. For instance, in April 2024, according to Allergy UK, a UK-based national charity, more than 21 million people in the UK are affected by allergies, which became the most commonly reported chronic health condition in 2022, and projections indicate that by 2026, half of Europe's population will experience at least one allergy. Therefore, the rising prevalence of chronic diseases is driving the growth of actimmune industry.

Key Players In The Global Actimmune Market

Major companies operating in the actimmune market are Amgen Inc.

What Are Latest Mergers And Acquisitions In The Actimmune Market?

In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics plc for a deal of $27.8 billion. Through this acquisition, Amgen Inc. aims to expand its portfolio in oncology and cardiovascular treatments while enhancing its biotechnology and drug development capabilities for future growth. Horizon Therapeutics plc is an Ireland-based biopharmaceutical company that specializes in actimmune, a treatment for rare diseases like chronic granulomatous disease (CGD) and osteopetrosis.

What Defines the Actimmune Market?

The actimmune market consists of sales of products such as subcutaneous injections and single-use vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Actimmune Market Report 2026?

The actimmune market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the actimmune industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.